Event Information

Emerging Immunotherapy Approaches in 1st Line Maintenance Therapy for Advanced UC

Type
Webinar
Event Description

Objectives:

  • Differentiate the clinical trial design of 1L UC studies
  • Review efficacy and safety outcomes of 1L UC trial results reported in 2020
  • Discuss factors involved in implementing 1L maintenance for UC patients

Speakers:

Srikala Sridhar MD, MSc, FRCPC
Medical Oncologist, Princess Margaret Cancer Center
Associate Professor, University of Toronto
Chair, GU Medical Oncologists of Canada

Nimira Alimohamed MD, FRCPC
Program Director, Medical Oncology Residency Training Program
Clinical Associate Professor, University of Calgary Chair, Southern Alberta GU Tumour Group Staff
Medical Oncologist, Tom Baker Cancer Centre

 

√ Accreditation: Section 1 Group Learning
 

info tal.erdman@cua.org

**This webinar is reserved for healthcare professionals and sponsoring companies. Registration will be vetted before event links are provided to participants. 

Sponsor: EMD Serono Pfizer

REGISTER

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy